Stockscreener 앱 받기
105.98
0.70%
0.74
시간 외 거래:
106.44
0.46
+0.43%
전일 마감가:
$105.24
열려 있는:
$105.5
하루 거래량:
2.02M
Relative Volume:
0.99
시가총액:
$20.70B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
24.09
EPS:
4.3988
순현금흐름:
$945.58M
1주 성능:
+13.37%
1개월 성능:
+21.58%
6개월 성능:
+77.97%
1년 성능:
+28.71%
1일 변동 폭
$103.81
$106.40
1주일 범위
$91.16
$106.47
52주 변동 폭
$53.56
$106.47
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
105.98 | 20.65B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Will Incyte Corporation stock outperform Dow Jones indexBull Run & Weekly High Momentum Picks - newser.com
How Incyte Corporation stock responds to policy changesWeekly Trend Report & Smart Money Movement Alerts - newser.com
Key metrics from Incyte Corporation’s quarterly dataWeekly Risk Report & AI Powered Trade Plan Recommendations - newser.com
Incyte EVP Denton sells $60,613 in stock By Investing.com - Investing.com Nigeria
Incyte EVP Denton sells $60,613 in stock - Investing.com
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema - The Joplin Globe
Leading vs lagging indicators on Incyte Corporation performanceJuly 2025 Summary & Real-Time Volume Triggers - newser.com
Can Incyte Corporation (ICY) stock attract analyst upgradesShort Setup & Smart Money Movement Alerts - newser.com
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Incyte stock hits 52-week high at 103.93 USD - Investing.com
Will Incyte Corporation stock see PE expansionWatch List & Technical Buy Zone Confirmation - newser.com
Incyte Unveils Game-Changing mCALR Trials – What It Means for Blood Cancer Treatment! - Smartkarma
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J - GuruFocus
Incyte (INCY) Receives Raised Price Target from Piper Sandler | - GuruFocus
Incyte (NASDAQ:INCY) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Incyte aboard, SMARCA2 shift by Prelude enshrouds Foghorn - BioWorld MedTech
Prelude Therapeutics Signs Option Agreement with Incyte - TipRanks
Incyte (NASDAQ:INCY) Upgraded by Guggenheim to Buy Rating - MarketBeat
Incyte (INCY) Secures Option for JAK2V617F Program in $910M Deal - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program - Investing.com
Incyte (INCY) Secures Exclusive Option on JAK2V617F Program - GuruFocus
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com UK
Prelude Therapeutics Announces Strategic Updates: Prioritizes JAK2V617F and KAT6A Programs, Pauses SMARCA2 Development and Secures $60 Million from Incyte Option Agreement - Quiver Quantitative
Hussman Strategic Advisors Inc. Boosts Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage - Insider Monkey
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call - Barchart.com
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corporation (INCY) Stock forecasts - Yahoo! Finance UK
Is Incyte Corporation (ICY) stock dividend growth reliableJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Incyte Corp. Stock Climbs 8.7%, Outperforms Peers - 富途牛牛
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte (INCY) Upgraded to Buy by Guggenheim, Price Target Set at $125 | INCY Stock News - GuruFocus
Incyte stock jumps on promising cancer data - Investing.com
Is It Too Late to Ride INCY’s Upsurge? - timothysykes.com
Incyte (INCY) Shares Rise Following Promising Myelofibrosis Data - GuruFocus
INCY: Promising Myelofibrosis Treatment Bolsters Incyte's Prospe - GuruFocus
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting - Yahoo Finance
Is Incyte Corporation building a consolidation basePortfolio Value Report & AI Enhanced Trading Alerts - newser.com
What’s next for Incyte Corporation stock priceEarnings Overview Summary & Weekly Breakout Stock Alerts - newser.com
Incyte Corporation $INCY Shares Sold by South Dakota Investment Council - MarketBeat
Bessemer Group Inc. Reduces Stock Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corp (INCY) Stock Price, Trades & News - GuruFocus
Can Incyte Corporation stock hit record highs againPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Pharmaceutical Stocks To Keep An Eye OnOctober 28th - MarketBeat
How Incyte Corporation stock performs in rising dollar environmentJuly 2025 Recap & AI Based Trade Execution Alerts - newser.com
Nisa Investment Advisors LLC Boosts Stock Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views - MSN
Incyte to Present at Upcoming November 2025 Investor Conferences - BioSpace
Is Incyte Corporation (ICY) stock undervalued by metricsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
2.17%
자본화:
|
볼륨(24시간):